What Do the Data Tell Us:
What Can We Learn from
the Latest Colorectal
Cancer Screening Rate
Trends Over Time?

November 3, 2021 – 1:00-2:00 PM ET
2021 80% in Every Community Conference &
NCCRT Annual Meeting Pre-meeting Session
Purpose of Today’s Session

• Learn how we are doing as a nation on our efforts to reach an 80% colorectal cancer screening rate.
• Hear from four experts on the latest data and trends from key national data sets: NHIS, BRFSS, UDS, and HEDIS.
• Q&A
Presenters

**Jordan Karlitz, MD (Moderator)**
GI Division Chief, Denver Health Medical Center; and Associate Professor at the University of Colorado School of Medicine; NCCRT Steering Committee

**Lisa Richardson, MD, MPH**
Director, Division of Cancer Prevention and Control, Centers for Disease Control and Prevention, NCCRT Steering Committee

**Sepheen Byron**
Assistant Vice President, Performance Measurement, National Committee for Quality Assurance

**Neeraj Deshpande MBBS, MPH, MHA**
Public Health Analyst, Quality Recognition and Health Promotion Team, Bureau of Primary Health Care/Office of Quality Improvement, DHHS/Health Resources and Services Administration

**Stacey Fedewa, PhD**
Scientific Director, Screening and Risk Factors Research, American Cancer Society, Inc.
Virtual Housekeeping

- The event is being recorded. The replay and slides will be made available on www.nccrt.org within a few days.
- All participants are muted.
- Submit questions through the Q&A box at any time.
- Please complete our evaluation.

Funding for this webinar was made possible (in part) by the Centers for Disease Control and Prevention. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services, nor does the mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.
The NCCRT Data & Progress webpage provides up-to-date statistics on colorectal cancer screening, incidence, mortality, and geographic distribution information.

nccrt.org/data-progress
Colorectal Cancer Deaths and Cases

Colorectal Cancer Cases and Deaths, All Ages, All Races/Ethnicities, Both Sexes, 1999-2018

Health People 2020 Target: 14.5

Source: CDC Data visualization
2020 Behavioral Risk Factor Surveillance System (BRFSS) Colorectal Cancer Screening Overview

- First time questions about FIT-DNA test and computed tomography (CT) colonography included
- In adults ages 50-75:
  - 72.1% - Up to date with colorectal cancer screening (all test types)*
  - 19.3% Never Screened
- 69.7% Up to date with colorectal cancer screening by previous year’s definition**

* including FIT-DNA, CT (virtual) colonography
** the percentage of adults aged 50 to 75 who were up-to-date with fecal immunochemical test (FIT), sigmoidoscopy, and colonoscopy in 2020

7 in 10 U.S. Adults

Up to Date with Colorectal Cancer Screening
Adults 50-75 Up-to-Date Using USPSTF Recommendation*

* including FIT-DNA, CT (virtual) colonography
Reported Colorectal Cancer (CRC) Screening Test Use By Age and Race*

**Percent CRC Screening Test Use by Age**

- 50-64: 66.4%
- 65-75: 82.5%
- Overall: 72.1%

**Percent CRC Screening Use by Race**

- American Indian/Alaska Native: 63.1%
- Asian/Pacific Islander: 64.3%
- Black, non-Hispanic: 75.4%
- Hispanic: 64.9%
- Other/multiracial: 66.1%
- White, Non-Hispanic: 73.8%

* Age standardized
Reported Colorectal Cancer Screening Test Use By Gender*

* Age standardized
Reported Colorectal Cancer (CRC) Screening Test Use By Education and Income*

**Percent of CRC Screening Test Use by Education**

- College graduate: 76.5%
- Some college/Technical school: 73.6%
- High School/GED: 69.0%
- Less than high school: 64.4%

*Age standardized

**Percent CRC Test Use by Income**

- ≥75,000: 76.4%
- 50,000-74,999: 73.6%
- 35,000-49,999: 70.5%
- 15,000-34,999: 67.1%
- <15,000: 66.7%

*Age standardized*
Reported Colorectal Cancer Screening Test Use By Health Insurance Status*

* Age standardized
Reported CRC Screening Test Used By Regular Health Provider Status*

Percent CRC Test Use By Regular Health Provider Status

Yes: 76.2%
No: 41.4%

* Age standardized
Thank you!

Go to the official federal source of cancer prevention information:
www.cdc.gov/cancer
HEDIS® Colorectal Cancer Screening Measure

Sepheen Byron
Assistant Vice President, Performance Measurement
National Committee for Quality Assurance

National Colorectal Cancer Roundtable
November 2021
HEDIS®
Healthcare Effectiveness Data and Information Set

Tool used by over 90 percent of America’s health plans

Allows for comparison of health plans across important dimensions of care

- Access and availability of care
- Preventive services
- Chronic disease management
- Behavioral health and substance use
- Care coordination
- Utilization of health care
Colorectal Cancer Screening

Current measure description

Adults ages 50-75 years who had appropriate screening for colorectal cancer:

▸ **Fecal occult blood test** or **fecal immunochemical test** during the year
▸ **FIT-DNA test** within the past three years
▸ **Flexible sigmoidoscopy** within the past five years
▸ **CT colonography** within the past five years
▸ **Colonoscopy** within the past 10 years

Stratify by **race and ethnicity**
Medicare plans stratify by **socioeconomic status**

**Product Lines**
Commercial, Medicare

**Data Collection Method**
Administrative
Hybrid
Electronic Clinical Data Systems

**Required Benefits**
Medical
Colorectal Cancer Screening *amid the COVID-19 Pandemic*

<table>
<thead>
<tr>
<th>Year</th>
<th>Commercial</th>
<th>Medicare</th>
</tr>
</thead>
<tbody>
<tr>
<td>2018</td>
<td>62.1</td>
<td>72.0</td>
</tr>
<tr>
<td>2019</td>
<td>63.7</td>
<td></td>
</tr>
<tr>
<td>2020</td>
<td>61.4*</td>
<td>71.1</td>
</tr>
</tbody>
</table>

*Statistically significant*
Evolving HEDIS to Use More Electronic Clinical Data

What are we striving towards?

- Leverage more and better data into greater insight
- Foster patient-specific care
- Align with interoperability and value-based payment models
- Decrease measurement burden

Get to better measures
**Updated Guidelines for Colorectal Cancer Screening**

<table>
<thead>
<tr>
<th>Population</th>
<th>Recommendation</th>
<th>Grade</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adults ages 45 to 49 years</td>
<td>The USPSTF recommends screening for colorectal cancer in adults aged 45 to 49 years.</td>
<td>B</td>
</tr>
<tr>
<td>Adults ages 50 to 75 years</td>
<td>The USPSTF recommends screening for colorectal cancer in all adults aged 50 to 75 years.</td>
<td>A</td>
</tr>
<tr>
<td>Adults ages 76 to 85 years</td>
<td>The USPSTF recommends that clinicians selectively offer screening for colorectal cancer in adults aged 76 to 85 years. Evidence indicates that the net benefit of screening all persons in this age group is small. In determining whether this service is appropriate in individual cases, patients and clinicians should consider the patient's overall health, prior screening history, and preferences.</td>
<td>C</td>
</tr>
</tbody>
</table>

U.S. Preventive Services Task Force, May 2021
# Changes Posted for Public Comment

**HEDIS MY 2022 Technical Update**

## Denominator
Members 45 - 75 years of age by December 31 of the measurement year

## Age Stratifications
- Ages 45-49 years
- Ages 50-75 years
- Total

## Product Lines
- Commercial
- Medicare
- Medicaid

## Data Collection
- Drop Hybrid Reporting Method for MY 2022
- Establish ECDS-only Reporting for MY 2023
Agenda

• UDS 2020 highlights

• Colorectal Cancer (CRC) screening in 2020

• Colorectal Cancer (CRC) in previous years

• Next Steps
HRSA Health Center Program
Data
Highlights in 2020
Health Center Program highlights in 2020

- 28.6 million patients served
- 86 million in-patient visits
- 29 million virtual visits
- 11.3 million Dental visits
- 14.1 million Mental health visits
- 1.7 million Substance Use Disorder visits
- 99% health centers utilized telemedicine
- 24% Medical visits conducted virtually, 52% Mental health visits conducted virtually
- 33% Substance Use Disorder visits conducted virtually

Source: Uniform Data System, 2020
Colorectal Cancer Screening in 2020
Served over **6 million** patients age 50-75

Over **2.4 million** patients met screening criteria

**40.09%** patients met screening criteria nationally

Source: Uniform Data System, 2020
2020 UDS Colorectal Cancer eCQM: CMS130v6

Source: Uniform Data System, 2020
### 2020 UDS Colorectal Cancer eCQM: CMS130v6 Compliant Slide

<table>
<thead>
<tr>
<th>State Abbreviation</th>
<th>CRC Screening rate</th>
</tr>
</thead>
<tbody>
<tr>
<td>AS</td>
<td>0%</td>
</tr>
<tr>
<td>PW</td>
<td>0%</td>
</tr>
<tr>
<td>MH</td>
<td>0%</td>
</tr>
<tr>
<td>FM</td>
<td>17%</td>
</tr>
<tr>
<td>VI</td>
<td>20%</td>
</tr>
<tr>
<td>MP</td>
<td>21%</td>
</tr>
<tr>
<td>AL</td>
<td>25%</td>
</tr>
<tr>
<td>NV</td>
<td>28%</td>
</tr>
<tr>
<td>UT</td>
<td>29%</td>
</tr>
<tr>
<td>OK</td>
<td>31%</td>
</tr>
<tr>
<td>GA</td>
<td>31%</td>
</tr>
<tr>
<td>AR</td>
<td>33%</td>
</tr>
<tr>
<td>KS</td>
<td>33%</td>
</tr>
<tr>
<td>TX</td>
<td>34%</td>
</tr>
<tr>
<td>MS</td>
<td>34%</td>
</tr>
<tr>
<td>TN</td>
<td>35%</td>
</tr>
<tr>
<td>NC</td>
<td>35%</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>State Abbreviation</th>
<th>CRC Screening rate</th>
</tr>
</thead>
<tbody>
<tr>
<td>MO</td>
<td>36%</td>
</tr>
<tr>
<td>CO</td>
<td>37%</td>
</tr>
<tr>
<td>CA</td>
<td>37%</td>
</tr>
<tr>
<td>WY</td>
<td>37%</td>
</tr>
<tr>
<td>LA</td>
<td>38%</td>
</tr>
<tr>
<td>IL</td>
<td>38%</td>
</tr>
<tr>
<td>NJ</td>
<td>39%</td>
</tr>
<tr>
<td>FL</td>
<td>40%</td>
</tr>
<tr>
<td>AZ</td>
<td>40%</td>
</tr>
<tr>
<td>MN</td>
<td>40%</td>
</tr>
<tr>
<td>HI</td>
<td>40%</td>
</tr>
<tr>
<td>NE</td>
<td>40%</td>
</tr>
<tr>
<td>WA</td>
<td>40%</td>
</tr>
<tr>
<td>PA</td>
<td>40%</td>
</tr>
<tr>
<td>PR</td>
<td>41%</td>
</tr>
<tr>
<td>SC</td>
<td>41%</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>State Abbreviation</th>
<th>CRC Screening rate</th>
</tr>
</thead>
<tbody>
<tr>
<td>IN</td>
<td>41%</td>
</tr>
<tr>
<td>DC</td>
<td>41%</td>
</tr>
<tr>
<td>AK</td>
<td>42%</td>
</tr>
<tr>
<td>OH</td>
<td>42%</td>
</tr>
<tr>
<td>NM</td>
<td>42%</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>State Abbreviation</th>
<th>CRC Screening rate</th>
</tr>
</thead>
<tbody>
<tr>
<td>WI</td>
<td>43%</td>
</tr>
<tr>
<td>ID</td>
<td>43%</td>
</tr>
<tr>
<td>IA</td>
<td>44%</td>
</tr>
<tr>
<td>KY</td>
<td>44%</td>
</tr>
<tr>
<td>MD</td>
<td>45%</td>
</tr>
<tr>
<td>VA</td>
<td>45%</td>
</tr>
<tr>
<td>OR</td>
<td>45%</td>
</tr>
<tr>
<td>MT</td>
<td>46%</td>
</tr>
<tr>
<td>ND</td>
<td>46%</td>
</tr>
<tr>
<td>NY</td>
<td>46%</td>
</tr>
<tr>
<td>MI</td>
<td>47%</td>
</tr>
<tr>
<td>CT</td>
<td>48%</td>
</tr>
<tr>
<td>MA</td>
<td>49%</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>State Abbreviation</th>
<th>CRC Screening rate</th>
</tr>
</thead>
<tbody>
<tr>
<td>WV</td>
<td>51%</td>
</tr>
<tr>
<td>SD</td>
<td>51%</td>
</tr>
<tr>
<td>RI</td>
<td>54%</td>
</tr>
<tr>
<td>GU</td>
<td>56%</td>
</tr>
<tr>
<td>DE</td>
<td>57%</td>
</tr>
<tr>
<td>NH</td>
<td>59%</td>
</tr>
<tr>
<td>VT</td>
<td>59%</td>
</tr>
<tr>
<td>ME</td>
<td>61%</td>
</tr>
</tbody>
</table>
Frequency distribution of health centers by screening percentage
2020 UDS Colorectal Cancer eCQM: CMS130v6: Urban vs Rural (Health Center Program only)

Source: Uniform Data System, 2020
2020 UDS Colorectal Cancer eCQM: CMS130v6
By PCMH status (Health Center Program only)

Source: Uniform Data System, 2020
Change in no of patients screened and CRC screening percentage (2020 vs 2019)

Source: Uniform Data System, 2020
Colorectal Cancer Screening in previous years
UDS Colorectal Cancer screening rates eCQM: CMS130v6

Source: Uniform Data System, 2020
UDS Colorectal Cancer screening rates eCQM: CMS130v6

Source: Uniform Data System, 2020
Next Steps
Next Steps

• Understanding from health centers
  ▪ What were some of the best practices that helped them maintain or increase their screening rates?
  ▪ Did patients have any preference for any particular screening option?
  ▪ How do they plan to sustain those activities/interventions?

• Provide technical assistance to health centers
• Continue to establish and foster partnerships for achieving our goals
Thank You!

Neeraj Deshpande MBBS, MPH, MHA
Public Health Analyst/Office of Quality Improvement (OQI)
Bureau of Primary Health Care (BPHC)
Health Resources and Services Administration (HRSA)

ndeshpande@hrsa.gov
(301) 4430497

bphc.hrsa.gov

Sign up for the Primary Health Care Digest
Connect with HRSA

Learn more about our agency at:

www.HRSA.gov

Sign up for the HRSA eNews

FOLLOW US:
What do the data tell us?
National Health Interview Survey

NATIONAL COLORECTAL CANCER ROUNDTABLE

November, 2021
Stacey Fedewa, PhD
Surveillance and Health Equity Sciences
American Cancer Society
National Health Interview Survey (Historical)

- In-person, household survey among non-institutionalized adults
- Self-reported CRC screening data every 2-3 years
  - Colonoscopy
  - Sigmoidoscopy
  - FIT/gFOBT (hereafter **FIT**)
  - CT colonography (added in 2010)
  - sDNA/Cologuard (added in 2018)
National Health Interview Survey: Recent/Updates

- 2019: Change in survey design, CRC screening questions, and rotation
- 2020: CRC screening data not collected, in-person → telephone → some in-person
  - Changes in response rates
  - Changes on respondent characteristics (more educated)
  - Additional weighting
- 2021: CRC screening data are collected, mix of in-person/ telephone

3.cancer.org
% Up-to-date CRC Screening 50-75 years, NHIS 2000-2019

Change in Survey Design and CRC screening questions
Pre-Pandemic Progress

NH White
Black
Asian
Hispanic

College Grad
Some College
HS
<HS
Pre-Pandemic Progress: Insurance

% Up-to-date with CRC Screening

- Medicare+Private
- Medicare alone or dual
- Private
- Medicaid
- Uninsured

NHIS 2019-2021: Proportion of Adults Reporting PCP Visit in Past Year According to Interview Quarter


Source: National Center for Health Statistics, National Health Interview Survey
NHIS 2019-2021: Proportion of Adults Reporting PCP Visit in Past Year According to Interview Quarter

Note the scale

<table>
<thead>
<tr>
<th>Year</th>
<th>Interview Quarter</th>
<th>Proportion (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>2019</td>
<td>Q1, Jan-Mar</td>
<td></td>
</tr>
<tr>
<td>2019</td>
<td>Q2, Apr-Jun</td>
<td></td>
</tr>
<tr>
<td>2019</td>
<td>Q3, Jul-Sep</td>
<td></td>
</tr>
<tr>
<td>2019</td>
<td>Q4, Oct-Dec</td>
<td></td>
</tr>
<tr>
<td>2020</td>
<td>Q1, Jan-Mar</td>
<td></td>
</tr>
<tr>
<td>2020</td>
<td>Q2, Apr-Jun</td>
<td></td>
</tr>
<tr>
<td>2020</td>
<td>Q3, Jul-Sep</td>
<td></td>
</tr>
<tr>
<td>2020</td>
<td>Q4, Oct-Dec</td>
<td></td>
</tr>
<tr>
<td>2021</td>
<td>Q1, Jan-Mar</td>
<td></td>
</tr>
</tbody>
</table>

Source: National Center for Health Statistics, National Health Interview Survey

Conclusions

• Pre-pandemic increases in CRC screening, especially in some groups with lower screening rates and more barriers

• COVID-19 Pandemic influenced survey mode, response rates, and respondent characteristics
Thank you
Please submit your questions in the Q&A box.
NCCRT National Meeting

80% in Every Community Conference & NCCRT Annual Meeting – Nov. 15-17, 2021

Presentations by nationally known experts, thought leaders, and decision makers on CRC screening policy and delivery.

nccrt.org/events/
The 2022 80% in Every Community National Achievement Awards

Submit your nominations by Nov. 19!

nccrt.org/awards
Thank You!

Questions? Contact nccrt@cancer.org